Prosecution Insights
Last updated: November 20, 2026
Application No. 18/348,312

SYNERGISTIC ANTIFOULANT COMPOSITIONS AND METHODS OF USING THE SAME

Non-Final OA §102§103§112
Filed
Jul 06, 2023
Priority
Jul 08, 2022 — CN 202210804714.2
Examiner
ANTHONY, JOSEPH DAVID
Art Unit
1764
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Ecolab USA Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
79%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
755 granted / 1032 resolved
+8.2% vs TC avg
Moderate +6% lift
Without
With
+5.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
33 currently pending
Career history
1065
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
35.7%
-4.3% vs TC avg
§102
24.9%
-15.1% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1032 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of substitutional imidazoline species (claims 1-8, 12 and 14-15) in the reply filed on 08/03/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8, 12 and 14-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Independent claim 1 is indefinite for the following reasons. The limitation of: “a first inhibitor compound comprising a stable nitroxide radical or a derivative thereof;” [Emphasis added] is indefinite because the metes and bounds of what is meant by “a stable nitroxide radical” is unknown. Stable in regard to what and under what conditions? Furthermore, the sub-limitation of: “or a derivative thereof;” is also indefinite because its metes and bounds is completely unknown. As way of illustration only, is the pyrolysis product of a stable nitroxide radical (i.e. carbon), encompassed by the limitation of: “or a derivative thereof;”? The limitation of: “a second inhibitor compound comprising phenothiazine or a derivative thereof;” is also indefinite because its metes and bounds is completely unknown. As way of illustration only, is the pyrolysis product of a phenothiazine (i.e. carbon), encompassed by the limitation of: “or a derivative thereof;”? The limitation of: “a functional solvent comprising a fouling removing agent selected from the group consisting of a substitutional imidazoline, a phthalate, a sulfone, and combinations thereof.” [Emphasis added]. What is meant by a “functional” solvent? The Examiner suggests the modifying word “functional” be deleted from said limitation. Furthermore, what is a “substitutional” imidazoline? Is Applicant trying to limit the scope of the imidazoline compound to only substituted imidazoline compounds and if so, what are these substituted moieties? Dependent claim 12 is indefinite in regard to the limitation of: “The composition of claim 1, further comprising an additional solvent selected from the group consisting of water, an ester, an aromatic, an aliphatic, an amide, an acylamide, an alcohol, a liquid polymer, and combinations thereof.” [Emphasis added]. By the sub-limitation “further comprising an additional solvent”, is Applicant implying that the solvent actually claimed in independent claim 1 is NOT anyone of: “water, an ester, an aromatic, an aliphatic, an amide, an acylamide, an alcohol, a liquid polymer, and combinations thereof.”? If said is the case, what are the metes and bounds of the solvent component actually claimed in independent claim 1? Furthermore, what is the metes and bounds of the Markush species of: “an aromatic, an aliphatic,”? Are these aromatic hydrocarbons, aliphatic hydrocarbons or something completely different? All other claims are also being rejected here because they are either directly or indirectly dependent on a rejected base claim. Claim Rejections - 35 USC § 102 Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-8, 12 and 14-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hammon et al. WO 02/051784 A1. WO 02/051784 A1 (i.e. WO) discloses a method for producing acrylic acid by heterogeneously catalysed gas phase partial oxidation of at least one C3 precursor with molecular oxygen. The product gas mixture containing acrylic acid is cooled and subsequently subjected to either fractionating condensation or a rectification process. Phenothiazine and at least one phenolic composition is introduced into the column head or in the vicinity of the column head the rectification or condensation column (n). Applicant’s claims are deemed to be directly anticipated over Example 4 (comparative) and Example 5 (comparative). Also see Table 1. In Example 4 (comparative) the acrylic acid produced by the process of Example 2 is further stabilized in the distillation step by the addition of a polymerization inhibiting solution comprising: 5 g/l of phenothiazine, 7 g/l of hydroquinone monomethyl ether, and 1 g/l of 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (HTEMPO). Please note that the process of Example 2, the production of acrylic acid employs a solvent mixture comprising: 58.8% by weight diphenyl ether, 21.2% by weight diphenyl and 20% by weight dimethylphthalate (which reads on applicant’s functional solvent wherein the fouling removing agent is a phthalate as set forth in independent claim 1). As such, Applicant’s claims are clearly anticipated by the composition formed after the addition of said polymerization inhibiting solution comprising: 5 g/l of phenothiazine, 7 g/l of hydroquinone monomethyl ether, and 1 g/l of 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (HTEMPO) to the acrylic acid product contained in solvent mixture of diphenyl ether, diphenyl and dimethylphthalate. Example 5 (comparative) is identical to Example 4 (comparative) except that the the addition of the polymerization inhibiting solution comprises only two inhibitors instead of three inhibitors used in Example 4. Example 5 (comparative) uses an polymerization inhibiting solution which comprises: 6 g/l of phenothiazine and 1 g/l of 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (HTEMPO). As such, Applicant’s claims are clearly anticipated by the composition formed after the addition of said polymerization inhibiting solution comprising: 6 g/l of phenothiazine and 1 g/l of 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (HTEMPO) to the acrylic acid product contained in solvent mixture of diphenyl ether, diphenyl and dimethylphthalate. Claim(s) 1-8, 12 and 14-15 are rejected under 35 U.S.C. 103 as being unpatentable over Chretien et al. U.S. Patent Application Publication No.: 2019/0023641 A1 optionally in view of Hammon et al. WO 02/051784 A1. Chretien et al. discloses the use of at least two phenol derivatives jointly with at least one ancillary polymerization inhibitor which is different from these two phenol derivatives and particularly is selected from phenol derivatives, amine derivatives, thiazine derivatives, nitroso compounds, N-oxyl derivatives, metal salts, quinone derivatives, and mixtures thereof, to inhibit the polymerization of ethylenically unsaturated monomers comprising at least one heteroatom, it being also possible for a dispersant to be incorporated. The present invention also relates to a corresponding polymerization-inhibiting composition and to the corresponding process for preparing ethylenically unsaturated monomers comprising at least one heteroatom, and particularly acrylic monomers, see abstract. A preferred thiazine derivative is phenothiazine (PTZ), see paragraph [0057] and Examples 5-6. Preferred N-oxyl derivatives are 2,2,6,6 tetramethyl-1-piperidine N-oxyl (TEMPO) and its derivatives: 4-hydroxy TEMPO (HTEMPO), 4-methoxy TEMPO, 4-oxo TEMPO or 4-amino TEMPO, di-tert-butyl nitroxide, 2,2,5,5-tetramethyl-3-oxopyrrolidine-oxyl, 2,2,6,6-tetramethyl-4-acetoxypiperidine oxyl, and 4,4′,4″-tris(2,2,6,6-tetramethylpiperidine-oxy)phosphate, see paragraph [0061] and claims 18-19. The polymerization-inhibiting composition preferably further contains at least one dispersant that can function as a solvent, surfactant, antifouling agent, anti-deposition agent etc.., see paragraph [0065]-[0068]. Some preferred dispersants are sulfonates, see paragraph [0069] and claim 12, and imidazolines, see paragraph [0076] and claim 12. Chretien et al. differ from Applicant’s claimed invention in that there does not seem to be a direct teaching (i.e. by way of an example) to a polymerization inhibiting composition that actually comprises an N-oxyl compound (e.g. (HTEMPO)), phenothiazine (PTZ), and a sulfonate and/or imidazoline dispersant all together. It would have been obvious to one having ordinary skill in the art to use Chretien et al.’s direct disclosure that the at least two phenol derivatives are used in combination with at least one ancillary polymerization inhibitor (e.g. N-oxyl compound (e.g. (HTEMPO)), phenothiazine (PTZ)), and preferably further in combination with at least one dispersant (e.g. sulfonates and imidazolines), as strong motivation to actually make a polymerization-inhibiting composition comprising: two phenol derivatives, an N-oxyl compound (e.g. (HTEMPO)) inhibitor, a phenothiazine (PTZ) inhibitor and at least one dispersant (e.g. sulfonates and imidazolines). Please note that it is well established by the courts that to use two or more compounds together (e.g. N-oxyl compound and phenothiazine), for the same purpose they are individually known to be used, is NOT inventive outside a showing of superior and unexpected results. In the alternative, Chretien et al. can optionally be combined with Hammon et al. WO 02/051784 A1 (described above), for Hammon et al. WO 02/051784 A1’s direct teaching that polymerization inhibiting combinations of a (HTEMPO)) inhibitor and a phenothiazine (PTZ) inhibitor is well known in the art, as further motivation for Chretien et al. to actually use a (HTEMPO)) inhibitor in combination with a phenothiazine (PTZ) inhibitor for the benefits such a combination would impart to the polymerization inhibiting combinations. Claim(s) 1-8, 12 and 14-15 are rejected under 35 U.S.C. 103 as being unpatentable over Marguerre et al. U.S. Patent No.: 10,221,255 B2 optionally in view of Hammon et al. WO 02/051784 A1. Marguerre et al. discloses a composition for the immediate stopping of a free-radical polymerization comprises a) an inhibitor for the free-radical polymerization selected from among phenothiazines, b) an aprotic solvent and c) an ionic liquid. It serves to stabilize free-radically polymerizable monomers against free-radical polymerization. For the immediate stopping of free-radical polymerizations, the composition is added to a free-radically polymerizing system, see abstract. Marguerre et al. discloses a preferred class of polymerization inhibitors are phenothiazines, see column 2,lines 18-45 and examples. Marguerre et al. also discloses that other effective polymerization inhibitors are N-oxyl compounds such as 2,2,6,6-tetramethylpiperazin-1-oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperazin-1-oxyl (HO-TEMPO), and 4-oxo-2,2,6,6-tetramethylpiperazin-1-oxyl (oxo-TEMPO), see column 8, line 66 to column 9, line 6. Marguerre et al. also discloses the preferable addition of an additive to the polymerization inhibitor composition wherein the additive can be a sulfonate and/or dimethyl phthalate. Table 6 directly teaches a polymerization inhibitor composition comprising phenothiazine and sulfolane, and another polymerization inhibitor composition comprising phenothiazine and dimethyl phthalate, see TABLE 6. Marguerre et al. differ from Applicant’s claimed invention in that there does not seem to be a direct teaching (i.e. by way of an example) to a polymerization inhibiting composition that actually comprises an N-oxyl compound (e.g. (HO-TEMPO)), phenothiazine (PTZ), and a sulfolane and/or dimethyl phthalate dispersant all together. It would have been obvious to one having ordinary skill in the art to use Marguerre et al. disclosure that (e.g. N-oxyl compound (e.g. (HO-TEMPO)) and phenothiazine (PTZ)) are highly effective polymerization inhibitors, and that (e.g. sulfonates and dimethyl phthalate) are preferable additives, as strong motivation to actually make a polymerization-inhibiting composition comprising: an N-oxyl compound (e.g. (HO-TEMPO)) inhibitor, a phenothiazine (PTZ) inhibitor and at least one additive (e.g. sulfonates and dimethyl phthalate). Please note that it is well established by the courts that to use two or more compounds together (e.g. N-oxyl compound and phenothiazine), for the same purpose they are individually known to be used, is NOT inventive outside a showing of superior and unexpected results. In the alternative, Marguerre et al. can optionally be combined with Hammon et al. WO 02/051784 A1 (described above), for Hammon et al. WO 02/051784 A1’s direct teaching that polymerization inhibiting combinations of a (HTEMPO) inhibitor (same as Marguerre et al.’s (HO-TEMPO)) and a phenothiazine (PTZ) inhibitor is well known in the art, as further motivation for Marguerre et al. to actually use a (HO-TEMPO)) inhibitor in combination with a phenothiazine (PTZ) inhibitor for the benefits such a combination would impart to the polymerization inhibiting combinations. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH DAVID ANTHONY whose telephone number is (571)272-1117. The examiner can normally be reached M-F: 10:00AM-6:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Arrie (Lanee) Reuther can be reached at 571-270-7026. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH D ANTHONY/Primary Examiner, Art Unit 1764
Read full office action

Prosecution Timeline

Jul 06, 2023
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12802830
OXIDATION AND CORROSION RESISTANT NUCLEAR FUEL
4y 9m to grant Granted Nov 17, 2026
Patent 12799339
Intumescent coating having improved low-temperature flexibility
4y 0m to grant Granted Nov 17, 2026
Patent 12790497
CORROSION INHIBITOR
4y 6m to grant Granted Nov 10, 2026
Patent 12781061
MODIFIED GRAPHENE AND GRAPHENE NANOPLATELET FOR ANTI-CORROSION COATINGS
4y 2m to grant Granted Nov 03, 2026
Patent 12781126
NON-TRIAZOLE COMPOUNDS AND METHODS FOR INHIBITING CORROSION USING NON-TRIAZOLE COMPOUNDS
3y 2m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
79%
With Interview (+5.5%)
2y 7m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1032 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month